SCYNEXIS (LTS:0L49) Change In Other Working Capital : $2.9 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Change In Other Working Capital?

SCYNEXIS's Change In Other Working Capital for the quarter that ended in Mar. 2024 was $-0.8 Mil. It means SCYNEXIS's Other Working Capital declined by $0.8 Mil from Dec. 2023 to Mar. 2024 .

SCYNEXIS's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was $-2.1 Mil. It means SCYNEXIS's Other Working Capital declined by $2.1 Mil from Dec. 2022 to Dec. 2023 .

SCYNEXIS Change In Other Working Capital Historical Data

The historical data trend for SCYNEXIS's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Change In Other Working Capital Chart

SCYNEXIS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Other Working Capital

Get a 7-Day Free Trial

-0.12

2.36

-2.14

SCYNEXIS Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Other Working Capital	Get a 7-Day Free Trial															-5.84	5.84	-	-2.14	-0.80

SCYNEXIS Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.9 Mil.

SCYNEXIS Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS (LTS:0L49) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

SCYX:USA 135A:Germany

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines